Revvity, Inc. (NYSE:RVTY) Stock Holdings Lifted by Timber Creek Capital Management LLC

Timber Creek Capital Management LLC lifted its holdings in shares of Revvity, Inc. (NYSE:RVTY) by 1.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 33,417 shares of the company’s stock after purchasing an additional 622 shares during the quarter. Timber Creek Capital Management LLC’s holdings in Revvity were worth $3,730,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. CIBC Asset Management Inc increased its position in Revvity by 3.5% in the fourth quarter. CIBC Asset Management Inc now owns 18,630 shares of the company’s stock worth $2,079,000 after buying an additional 637 shares during the period. Sanctuary Advisors LLC bought a new position in shares of Revvity during the fourth quarter worth about $209,000. Principal Securities Inc. increased its holdings in shares of Revvity by 54.9% in the 4th quarter. Principal Securities Inc. now owns 598 shares of the company’s stock worth $67,000 after acquiring an additional 212 shares during the period. Vontobel Holding Ltd. lifted its position in Revvity by 11.0% in the 4th quarter. Vontobel Holding Ltd. now owns 2,405 shares of the company’s stock valued at $268,000 after purchasing an additional 238 shares during the last quarter. Finally, Empowered Funds LLC boosted its stake in Revvity by 60.1% during the 4th quarter. Empowered Funds LLC now owns 2,839 shares of the company’s stock valued at $317,000 after purchasing an additional 1,066 shares during the period. Institutional investors and hedge funds own 86.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on RVTY shares. Barclays raised their price target on shares of Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. TD Cowen lifted their target price on Revvity from $141.00 to $144.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. KeyCorp increased their price target on Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Robert W. Baird lifted their price objective on shares of Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, Bank of America upgraded shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 target price for the company in a research report on Friday, December 13th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Revvity currently has a consensus rating of “Moderate Buy” and an average target price of $136.25.

Insider Transactions at Revvity

In related news, insider Tajinder S. Vohra sold 5,492 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the transaction, the insider now directly owns 19,652 shares of the company’s stock, valued at approximately $2,295,550.12. The trade was a 21.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Joel S. Goldberg sold 15,170 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the transaction, the insider now owns 33,400 shares in the company, valued at approximately $4,232,782. This represents a 31.23 % decrease in their position. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by insiders.

Revvity Stock Down 0.6 %

Shares of Revvity stock opened at $111.57 on Wednesday. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. Revvity, Inc. has a 12-month low of $97.32 and a 12-month high of $129.50. The firm has a market capitalization of $13.58 billion, a PE ratio of 50.48, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. The stock’s fifty day moving average is $116.99 and its 200-day moving average is $118.81.

Revvity (NYSE:RVTY) last announced its earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the previous year, the business earned $1.25 earnings per share. Equities analysts anticipate that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.25%. The ex-dividend date is Thursday, April 17th. Revvity’s dividend payout ratio (DPR) is currently 12.67%.

Revvity announced that its Board of Directors has initiated a stock buyback plan on Monday, November 4th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to repurchase up to 6.5% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.